Karo Pharma AB Financials
| KARBFDelisted Stock | USD 5.25 0.00 0.00% |
Karo |
Understanding current and past Karo Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Karo Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Karo Pharma's assets may result in an increase in income on the income statement.
The data published in Karo Pharma's official financial statements usually reflect Karo Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Karo Pharma AB. For example, before you start analyzing numbers published by Karo accountants, it's critical to develop an understanding of what Karo Pharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Karo Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Karo Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Karo Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Karo Pharma AB. Please utilize our Beneish M Score to check the likelihood of Karo Pharma's management manipulating its earnings.
Karo Pharma Stock Summary
Karo Pharma competes with Loandepot, Air Lease, Vita Coco, Oatly Group, and Constellation Brands. Karo Pharma AB develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. Karo Pharma AB was incorporated in 1987 and is headquartered in Stockholm, Sweden. Karo Pharma is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Klara Norra Kyrkogata |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | NYSE Composite |
| Website | www.karopharma.com |
| Phone | 46 1 03 30 23 10 |
| Currency | USD - US Dollar |
You should never invest in Karo Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Karo Pink Sheet, because this is throwing your money away. Analyzing the key information contained in Karo Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Karo Pharma Key Financial Ratios
Generally speaking, Karo Pharma's financial ratios allow both analysts and investors to convert raw data from Karo Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Karo Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Karo Pharma AB reports annually and quarterly.Karo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Karo Pharma's current stock value. Our valuation model uses many indicators to compare Karo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Karo Pharma competition to find correlations between indicators driving Karo Pharma's intrinsic value. More Info.Karo Pharma AB is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Karo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Karo Pharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Karo Pharma's earnings, one of the primary drivers of an investment's value.Karo Pharma Market Pulse
| Quote | 5.25 |
| Change(%) | 0.00 |
| Change | 0.00 |
| Open | 5.25 |
| Low | 5.25 |
| High | 5.25 |
| Volume | 0 |
| Exchange | PINK |
About Karo Pharma Financials
What exactly are Karo Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Karo Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Karo Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Karo Pharma investors may use each financial statement separately, they are all related. The changes in Karo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Karo Pharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Karo Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Karo has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Karo Pharma's financials are consistent with your investment objective using the following steps:- Review Karo Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Karo Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Karo Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Karo Pharma's stock is overvalued or undervalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Karo Pharma AB information on this page should be used as a complementary analysis to other Karo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Karo Pink Sheet
If you are still planning to invest in Karo Pharma AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karo Pharma's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |